China expands drug protection regime with rare-disease, paediatric medicine exclusivity framework
Draft implementing rules introduce market exclusivity periods of up to seven years for rare-disease drugs and up to two years for paediatric medicines
Draft implementing rules introduce market exclusivity periods of up to seven years for rare-disease drugs and up to two years for paediatric medicines